DOE OSTI · 23200966
Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial
Abstract
To identify patients with intermediate-risk prostate cancer (IRPC) benefiting from de-escalation of androgen deprivation therapy (ADT) and/or dose escalated radiation therapy (DERT), we performed a secondary analysis of a phase 3 trial by measuring biochemical failure (BF), distant metastases, prostate cancer–specific mortality, overall survival (OS), and distant metastases-free survival (DMFS) rates according to prognostic intermediate risk factors (IRF).
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Nabid, Abdenour, Carrier, Nathalie, Vigneault, Eric, Van Nguyen, Thu, Vavassis, Peter, others, and. 2021-11-15. Optimizing Treatment in Intermediate-Risk Prostate Cancer: Secondary Analysis of a Randomized Phase 3 Trial. https://doi.org/10.1016/j.ijrobp.2021.04.013
Cite the original work for its findings. Save a collection to share your selection of sources.